Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.45 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8945304 | 1.00 | MME (0.61) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL30600472 | 1.00 | MME (0.61) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL30123121 | 0.97 | MME (0.58) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL29788251 | 0.95 | MME (0.56) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL30662328 | 0.95 | MME (0.56) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| Dimethyl Sulfone SCHEMBL17165618 | 0.95 | MME (0.56) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| Dimethyl Sulfone SCHEMBL17165619 | 0.95 | MME (0.56) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL29406037 | 0.94 | MME (0.55) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL29725304 | 0.94 | MME (0.55) | MMESLC7A5TGFBR1ALDH1A1MAPT | |
| SCHEMBL29351939 | 0.92 | MME (0.53) | MMESLC7A5ALDH1A1MAPTLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090562-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089719-A1 | DNA VECTORS HAVING SPECIALIZED SECONDARY STRUCTURES FOR USE IN TREATING HYPOPHOSPHATASIA | RAMPART BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240181022-A1 | AMURINS LYSINS, AND LYSIN-ANTIMICROBIAL PEPTIDE (AMP) CONSTRUCTS ACTIVE AGAINST GRAM-NEGATIVE BACTERIA | AUROBAC THERAPEUTICS SAS (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-3690439-B1 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | PROCTER & GAMBLE (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4314020-A1 | AMURINS LYSINS, AND LYSIN-ANTIMICROBIAL PEPTIDE (AMP) CONSTRUCTS ACTIVE AGAINST GRAM-NEGATIVE BACTERIA | Contrafect Corporation (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-20220401514-A1 | ANTIMICROBIAL, BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE AND ACID-FAST BACTERIA | CONTRAFECT CORPORATION | 2022-12-22 | — | — | US | disclosed |
| US-20140303236-A1 | CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140271930-A1 | NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | THE PROCTER & GAMBLE COMPANY (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| US-5508382-A | SYNTHETIC CALCITONIN | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0452514-B1 | PEPTIDE AND PROCESS FOR PREPARING CYCLIC PEPTIDE | DAICEL CHEM (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5428129-A | Cyclization in presence of an alkali metal salt | DAICEL CHEMICAL INDUSTRIES (JP) | 1995-06-27 | — | — | US | disclosed |
| EP-0452514-A1 | PEPTIDE AND PROCESS FOR PREPARING CYCLIC PEPTIDE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | MME 3487/4885SLC7A5 1405/4885TGFBR1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.